BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update (PRNewswire) - May 15, 2025 - P=NA | N=NA | "The new pharmacogenomic were delivered in a oral presentation at the International Society for Cell & Gene Therapy (ISCT) 2025 Annual Meeting, in New Orleans. The data highlight the impact of the UNC13A genotype on clinical outcomes for ALS patients treated with NurOwn. The presentation was featured in the ISCT public announcement regarding the meeting, which indicated that the data were 'carefully reviewed and selected by the ISCT 2025 Planning Faculty, to explore the latest breakthroughs in the clinical translation of Mesenchymal Stem/Stromal Cells and how they will shape the future of cell therapies'."
Clinical data • Amyotrophic Lateral Sclerosis
|